Targeting a protein to improve immunotherapy for lung cancer
Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer
This study is looking at a new treatment for non-small cell lung cancer that uses a special antibody to help your immune system fight the cancer better, and it hopes to find a way to make current therapies work more effectively for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10882206 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy for non-small cell lung cancer (NSCLC) by targeting a specific protein called GARP that plays a role in immune dysfunction. The study aims to develop a monoclonal antibody, PIIO-1, which selectively inhibits the activity of transforming growth factor-beta (TGFβ) in the tumor microenvironment, thereby improving the immune response against cancer cells. By using advanced mouse models, researchers will evaluate how well this approach can overcome resistance to existing cancer therapies. Patients may benefit from a more effective treatment option that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded to standard immunotherapy treatments.
Not a fit: Patients with other types of lung cancer or those who have not been diagnosed with cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new immunotherapy option that significantly improves treatment responses for patients with non-small cell lung cancer.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could lead to meaningful advancements.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Li, Zihai — Ohio State University
- Study coordinator: Li, Zihai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.